Ginkgo Bioworks Holdings, Inc.(DNA)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Ginkgo Bioworks Holdings, Inc. (DNA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DNA at 18.8/100 on a 32-signal composite quality model, placing it at rank #2,802 of 2,962 stocks — the bottom half of the AI-ranked universe. DNA scores in the top quartile across institutional flow (94.3). Areas of concern include revenue growth (2.7) and profitability (5.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Ginkgo Bioworks Holdings, Inc. reports quarterly revenue of $20.2M, net income of $-46.7M, free cash flow of $-46.9M. Top institutional holders of DNA by reported 13-F value include BlackRock, VIKING GLOBAL INVESTORS, Erste Asset Management GmbH, based on the most recent SEC filings. DNA trades on the NYSE exchange and files with the SEC under CIK 1830214. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ginkgo Bioworks Holdings, Inc. directly from SEC EDGAR.